INmune Bio surged 75% after-hours as investors bet big on Phase 2 Alzheimer trial data due Monday. Its lead drug XPro targets inflammation in early-stage patients. With bullish sentiment on Stocktwits and prior hints of strong results, retail investors see major upside if the topline data delivers as hoped.